{
    "clinical_study": {
        "@rank": "46836", 
        "arm_group": {
            "arm_group_label": "Diagnostic (scintigraphy)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy prior to receiving ipilimumab therapy and at 12 weeks."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies aldesleukin imaging in viewing tumor growth in patients\n      with stage IV melanoma receiving ipilimumab therapy. New diagnostic procedures, such as\n      single-photon emission computed tomography (SPECT/CT), may be a less invasive way to check\n      for stage IV melanoma. Radioactive drugs, such as technetium Tc 99\n      hydrazinonicotinamide-tricine-linked interleukin-2, may carry radiation directly to cancer\n      cells and not harm normal cells. Giving 99mTc-HYNIC-IL2 with SPECT/CT may help find tumor\n      growth in patients with stage IV melanoma"
        }, 
        "brief_title": "Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab Therapy", 
        "condition": [
            "Recurrent Melanoma", 
            "Stage IV Melanoma"
        ], 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Feasibility/biodistribution of 99mTc-HYNIC-IL2 (technetium Tc 99\n      hydrazinonicotinamide-tricine-linked interleukin 2) scintigraphy in patients with metastatic\n      melanoma undergoing ipilimumab (IPI) therapy.\n\n      SECONDARY OBJECTIVES:\n\n      I. Correlation of tumor infiltrating lymphocyte (TIL) invasion (scintigraphy/histology) with\n      tumor diameter (Response Evaluation Criteria in Solid Tumors [RECIST]); description of\n      survival end points(progression free survival [PFS]/overall survival [OS] and 2 year\n      survival rate); and description of any clinical side effects associated with imaging.\n\n      TERTIARY OBJECTIVES:\n\n      I. Correlation of TIL invasion assessed by 99mTc-HYNIC-IL2 scintigraphy vs histology (total\n      and subsets of TIL), as well as screen for peripheral blood correlates.\n\n      OUTLINE:\n\n      Patients undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2\n      scintigraphy prior to receiving ipilimumab therapy and at 12 weeks.\n\n      After completion of study treatment, patients are followed up every 3 months for up to 2\n      years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologic proof of stage IV melanoma (pathology report confirmation) with plans to\n             initiate therapy with ipilimumab according to Food and Drug Administration (FDA)\n             approved guidelines with multiple lesions such that\n\n               -  Two of these lesions are in the same organ and at least one of these two lesions\n                  is measurable by CT imaging according to RECIST 1.1 OR\n\n               -  Three of these lesions are in different organs and at least one of these 3\n                  lesions is measurable by CT imaging according to RECIST 1.1\n\n          -  Patient eligible for and will be receiving ipilimumab as standard of care therapy\n\n          -  At most 2 prior systematic regimens in the metastatic setting\n\n          -  Absolute neutrophil count (ANC) >=1500 mL\n\n          -  Hemoglobin (Hgb) > 10 g/dL\n\n          -  Platelets (PLT) >= 50,000 mL\n\n          -  Aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)\n\n          -  Alkaline phosphatase =< 3 x ULN*; *up to 5 x allowed for patients with liver\n             metastases\n\n          -  Ability to provide informed consent\n\n          -  Willingness to return to Mayo Clinic Rochester for follow-up\n\n          -  Life expectancy >= 12 weeks\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2\n\n          -  For women of childbearing potential, a negative serum pregnancy test =< 7 days prior\n             to registration\n\n          -  Willingness to participate in mandatory imaging studies as well as provide mandatory\n             blood samples for correlative research\n\n          -  Tumor accessible for biopsy\n\n        Exclusion Criteria:\n\n          -  Uncontrolled or current infection\n\n          -  Known allergy to 99mTc-HYNIC-IL2 or components\n\n          -  Any of the following prior therapies with interval since most recent treatment:\n\n               -  Chemotherapy =< 3 weeks prior to registration\n\n               -  Biologic therapy =< 3 weeks prior to registration\n\n               -  Radiation therapy =< 3 weeks prior to registration\n\n          -  No more than 3 prior systematic regimens in the metastatic setting\n\n          -  Failure to fully recover from side effects of prior chemotherapy or surgery\n\n          -  Any of the following, as this regimen may be harmful to a developing fetus or nursing\n             child:\n\n               -  Pregnant women\n\n               -  Nursing women\n\n               -  Women of childbearing potential or their sexual partners who are unwilling to\n                  employ adequate contraception (condoms, diaphragm, birth control pills,\n                  injections, intrauterine device [IUD], surgical sterilization, subcutaneous\n                  implants, or abstinence, etc.)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01789827", 
            "org_study_id": "MC1274", 
            "secondary_id": "NCI-2013-00297"
        }, 
        "intervention": [
            {
                "arm_group_label": "Diagnostic (scintigraphy)", 
                "description": "Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies", 
                "intervention_name": "scintigraphy", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Diagnostic (scintigraphy)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Diagnostic (scintigraphy)", 
                "description": "Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies", 
                "intervention_name": "technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2", 
                "intervention_type": "Biological", 
                "other_name": "99mTc-HYNIC-IL2"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Interleukin-2"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 18, 2014", 
        "location": {
            "contact": {
                "email": "markovic.svetomir@mayo.edu", 
                "last_name": "Svetomir N. Markovic", 
                "phone": "507-538-7623"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic"
            }, 
            "investigator": {
                "last_name": "Svetomir N. Markovic", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Interleukin-2 Imaging As A Guide To Cancer Immunotherapy (Ipilimumab) In Advanced Melanoma: A Pilot Study", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Svetomir Markovic", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "95% binomial confidence interval will be constructed", 
            "measure": "Proportion of patients who develop a SLD (grade 2+ allergic reaction; grade 3+ anaphylaxis, grade 2+ injection site reaction, or a grade 3+ non-hematologic toxicity -not attributed to IPI treatment/progression or a co-morbid condition)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01789827"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Svetomir N. Markovic, M.D., Ph.D.", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns.", 
                "measure": "Adverse events, based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Examined using the Spearman rank correlation coefficients.", 
                "measure": "TIL invasion as determined by technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy with tumor burden (as determined by RECIST criteria)", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Tumor based biomarkers, and peripheral blood biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "description": "Spearman rank correlation coefficients will be used.", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}